Acta Scientific Women's Health (ASWH)(ISSN: 2582-3205)

Research Article Volume 2 Issue 3

Response Rates of Second Line Chemotherapy Platinum Resistant Ovarian Cancer in Sudan: 2013-2017

Mohammed Altyb Alshykh Aboshanab1, Mohammed Elmujtba Adam Essa Adam2,10*, Yousra Abdelmoniem Suleiman3,6, Shaima N Elgenaid4, Sherihan Mohammed Elkundi Osman2,5, Mustafa Mohamed Ali Hussein2,10, Sadia Kamal Albadawi Mohamed7, Mutwaly Defealla Yousif Haron2,10, Shiemaa Emad Abdelrahim6, Leena Abdelrahman Mohammed6, Manhal Habeeb Allah Osman6, Saja Hassan Mohamed6, Salma Ismaeel Rahama6, Saneyya Alsir Ali6, Sadiya Aminu Abdullahi6, Suha Abdallah Musa6, Ziryab Imad Taha Mahmoud9,10, Maha Ismail Elfadul Biuo 10, Abdelkareem A. Ahmed8,10,11*

1Faculty of Medicine, Alzaim Alazhari University, Khartoum, Sudan
2Faculty of Medicine, Alfashir University, Alfashir, Sudan
3Department of Clinical Oncology, Radiation and Isotopes Centre, Khartoum, Sudan
4Faculty of Medicine, University of Khartoum, Khartoum, Sudan
5Department of Molecular Medicine, Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan
6Faculty of Medicine, Omdurman Islamic University, Khartoum, Sudan
7Faculty of Medicine, University of Gezira, Wad Madani, Sudan
8Department of Physiology and Biochemistry, Faculty of Veterinary Science, University of Nyala, Nyala, Sudan
9Department of Internal Medicine and Rheumatology, Faculty of Medicine, University of Bahri, Khartoum, Sudan
10Department of Cancer Research and Awareness, Medical and Cancer Research Institute (MCRI),Nyala, Sudan
11Institute of Molecular Biology, University of Nyala, Nyala Sudan

*Corresponding Author: Mohammed Elmujtba Adam Essa Adam, Medical and Cancer Research Institute (MCRI) and Faculty of Medicine, AlFashir University, AlFashir, Sudan and Abdelkareem Abdallah Ahmed, Department of Physiology and Biochemistry, Faculty of Veterinary Science, University of Nyala and Medical and Cancer Research Institute (MCRI), Nyala, Sudan.

Received: December 27, 2019; Published: February 10, 2020

Reprints View PDF Related Articles

×

Abstract

Background: Ovarian carcinoma is the fifth leading cause of cancer death worldwide. The tumour mostly associated with various factors such as advanced age, early menstruation and gene association. We aimed to highlight the effectiveness of second-line chemotherapy in the management of ovarian cancer patients in Sudan.

Methods: The data collected from the hospital patients' records for five years period of time, including 62 patients with ovarian cancer who were treated by the second line platinum-resistant chemotherapy.

Results: The peak prevalence of the disease was found in Al-Jazeera state while the least in Al-Gadarif state. Age group above 55 years was the most affected group. The vast majority of patients showed partially reduction in mass's size. Others had complete disappearing of the mass or continuing of the tumor growth. All patients received a variant number of cycles of chemotherapy 3, 6, 2, 4, 5, 1 cycle respectively. 79.4% of the patients had achieved the normal value of cancer antigen 125 (CA125) levels after the treatment. In 50% of patients, cancer recurred after 1-2 months, 32.2% after 3-4 months and 17.8% after 5-6 months. The serous adenocarcinoma was found to be the most histological type whereas the least two types observed were clear cell carcinoma and serous papillary adenocarcinoma.

Conclusion: Our findings suggested that, Al-Jazeera state citizens were more vulnerable to resist first-line chemotherapy than others. The Sudanese patients with ovarian cancer may have a better response to Gemzar but further studies are needed to confirm this result.

Keywords: Adenocarcinoma; Gemzar; Ovarian Cancer; Second Line Chemotherapy, Sudanese Patients

×

References

  1. Jemal A., et al. “Cancer statistics, 2009”. CA: A Cancer Journal for Clinicians 59.4 (2009): 225-249.
  2. Liu JF., et al. “Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study”. The Lancet Oncology 15.11 (2014): 1207-1214.
  3. Luvero D., et al. “Treatment options in recurrent ovarian cancer: latest evidence and clinical potential”. Therapeutic Advances in Medical Oncology 6.5 (2014): 229-239.
  4. Kim A., et al. “Therapeutic strategies in epithelial ovarian cancer”. Journal of Experimental and Clinical Cancer Research: CR 31 (2012): 14.
  5. Matsuo K., et al. “Overcoming platinum resistance in ovarian carcinoma”. Expert Opinion on Investigational Drugs 19.11 (2010): 1339-1354.
  6. Doganay M., et al. “Krukenberg carcinoma metastasized from stomach resembling mucinous cystadenocarcinoma of the ovary”. Journal of Experimental Therapeutics and Oncology 11.1 (2015): 23-26.
  7. Coburn SB., et al. “International patterns and trends in ovarian cancer incidence, overall and by histologic subtype”. International Journal of Cancer 140.11 (2017): 2451-2460.
  8. La Vecchia C. “Ovarian cancer: epidemiology and risk factors”. European Journal of Cancer Prevention 26.1 (2017): 55-62.
  9. Shin DW., et al. “Secondary Breast, Ovarian, and Uterine Cancers After Colorectal Cancer: A Nationwide Population-Based Cohort Study in Korea”. Diseases of the Colon and Rectum 61.11 (2018): 1250-1257.
  10. Brogioni S., et al. “A special case of bilateral ovarian metastases in a woman with papillary carcinoma of the thyroid”. Experimental and Clinical Endocrinology and Diabetes 115.6 (2007): 397-400.
  11. Kaku T., et al. “Histological classification of ovarian cancer”. Medical Electron Microscopy 36 (2003): 9-17. 
  12. Della Pepa C., et al. “Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy”. Cancer Treatment Reviews 41.2 (2015): 136-143.
  13. Stuart GC. “First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer”. Gynecologic Oncology 90 (2003): S8-15.
  14. Spriggs D. “Optimal sequencing in the treatment of recurrent ovarian cancer”. Gynecologic Oncology 90 (2003): S39-44.
  15. Kroep JR. “Advances in epithelial ovarian cancer therapy”. Current Pharmaceutical Design 18 (2012): 3735-3740. 
  16. Rosen DG., et al. “Ovarian cancer: pathology, biology, and disease models”. Frontiers in Bioscience 14 (2009): 2089-2102. 
  17. Lengyel E. “Ovarian Cancer Development and Metastasis”. The American Journal of Pathology 177.3 (2010): 1053-1064. 
  18. Heitz F., et al. “Stage- and Histologic Subtype-Dependent Frequency of Lymph Node Metastases in Patients with Epithelial Ovarian Cancer Undergoing Systematic Pelvic and Paraaortic Lymphadenectomy”. Annals of Surgical Oncology 25.7 (2018): 2053-2059.
  19. Bookman MA., et al. “Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group”. Journal of Clinical Oncology 14.6 (1996): 1895-1902.
  20. Weroha SJ., et al. “Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma”. Gynecologic Oncology 122 (2011): 116-120.
  21. Housman G., et al. “Drug resistance in cancer: an overview”. Cancers 6 (2014): 1769-1792. 
  22. Luvero D., et al. “Treatment options in recurrent ovarian cancer: latest evidence and clinical potential”. Therapeutic Advances in Medical Oncology 6 (2014): 229-239.
  23. Prat J., et al. “Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics”. Human Pathology 80 (2018): 11-27.
  24. Longacre M., et al. “A comparative analysis of genetic and epigenetic events of breast and ovarian cancer related to tumorigenesis”. International Journal of Molecular Sciences 17.5 (2016): 759.
  25. Wu RC., et al. “Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions”. The Journal of Pathology 248.1 (2019): 41-50.
  26. Ahmed AA and Essa MEA. “Potential of epigenetic events in human thyroid cancer”. Cancer Genetics 239 (2019): 13-21.
  27. Ahmed A., et al. “An analytical, statistical study of thyroid cancer incidence in Sudan during 2005-2015”. Global Journal of Public Health Medicine 1.2 (2019): 96-106.
  28. Merritt MA., et al. “Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer”. International Journal of Cancer 122.1 (2008): 170-176. 
  29. Abuidris DO., et al. “Incidence and survival rates of ovarian cancer in low-income women in Sudan”. Molecular and Clinical Oncology 5.6 (2016): 823-828.
  30. Meisel JL., et al. “The role of systemic chemotherapy in the management of granulosa cell tumors”. Gynecologic Oncology 136.3 (2015): 505-511.
  31. van Altena AM., et al. “Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands”. Gynecologic oncology 125.3 (2012): 649-654.
  32. Doll KM., et al. “Detection of gynecologic cancers in indigent women in an urban inner-city hospital”. International Journal of Gynecological Cancer 22.7 (2012): 1113-1117.
  33. Bai H., et al. “Salvage Chemotherapy for Patients With Recurrent or Persistent Ovarian Clear Cell Carcinoma: A Retrospective Study of 164 Cases”. Medicine 94.27 (2015): e1121.
  34. Kodaz H., et al. “Increased dose single-agent gemcitabine in platinum-taxane resistant metastatic ovarian cancer”. Tumori 101.1 (2015): 36-40.
  35. Boisen MM., et al. “Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer”. International Journal of Gynecological Cancer 26 (2016): 626-631. 
  36. Anfinan N., et al. “Ten years experience in the management of borderline ovarian tumors at Tom Baker Cancer Centre”. Archives of Gynecology and Obstetrics 284.3 (2011): 731-735.
  37. Kheiri SA., et al. “Histopathological Pattern and Age Distribution, of Malignant Ovarian Tumor among Sudanese Ladies”. Open Access Macedonian Journal of Medical Sciences 6 (2018): 237-241.
  38. Ramus SJ., et al. “BRCA1/2 mutation status influences somatic genetic progression in inherited and sporadic epithelial ovarian cancer cases”. Cancer Research 63 (2003): 417-423.
  39. Lengyel E. “Ovarian cancer development and metastasis”. American Journal of Pathology 177.3 (2010): 1053-1064.
  40. Eisenkop SM and Spirtos NM. “The clinical significance of occult macroscopically positive retroperitoneal nodes in patients with epithelial ovarian cancer”. Gynecologic oncology 82 (2001): 143-149.
  41. Pujade-Lauraine E., et al. “Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial”. Journal of Clinical Oncology 32.13 (2014): 1302-1308.
  42. Gupta GP and Massague J. “Cancer metastasis: building a framework”. Cell 127.4 (2006): 679-695.
  43. Ata A., et al. “Nephrotic syndrome associated with gemcitabine use in a patient with ovarian cancer”. The American Journal of Case Reports 13 (2012): 268-270.
  44. Armstrong DK. “Relapsed ovarian cancer: challenges and management strategies for a chronic disease”. The Oncologist 7 (2002): 20-28.
  45. Moss EL., et al. “The role of CA125 in clinical practice”. Journal of Clinical Pathology 58 (2005): 308-312.
  46. Chaudhry P., et al. “Serum soluble Fas levels and prediction of response to platinum-based chemotherapy in epithelial ovarian cancer”. International Journal of Cancer 122.8 (2008): 1716-1721.
  47. Gronlund B., et al. “Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?” Journal of Clinical Oncology 22 (2004): 4051-4058.
  48. Gonzalez-Martin A and Group G. “Treatment of recurrent disease: randomized trials of monotherapy versus combination chemotherapy”. International Journal of Gynecological Cancer (2005): 241-246.
  49. Berg T., et al. “Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis”. Gynecologic Oncology (2019).
×

Citation

Citation: Mohammed Elmujtba Adam Essa Adam., et al. “Response Rates of Second Line Chemotherapy Platinum Resistant Ovarian Cancer in Sudan: 2013-2017”.Acta Scientific Women's Health 2.3 (2020): 03-10.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days

Indexed In





News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is December 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"

Contact US





Creative Commons License Open Access by Acta Scientific is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at https://actascientific.com

ff

Acta-Publications

ff

© 2021 Acta Scientific, All rights reserved.